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Abstract 27 
Skin and soft tissue infections (SSTIs) are a common infection among both outpatients 28 
and inpatients. The most frequently isolated bacterium in SSTIs was Staphylococcus 29 
aureus, and quarter of which was methicillin-resistant S. aureus (MRSA). In this study, 30 
to investigate molecular epidemiology of the 141 MRSA strains collected in the Japanese 31 
nationwide surveillance, we performed multiplex real-time PCR to detect staphylococcal 32 
cassette chromosome mec (SCCmec) type and virulence genes. The percentage of 33 
SCCmec type I, II, III, and IV was 1.4%, 52.5%, 5.7%, and 40.4%, respectively. 34 
According to the SCCmec type, we classified the strains into HA-MRSA (n = 84) and 35 
CA-MRSA (n = 57). Among the virulence genes, the percentage of enterotoxin C gene-36 
positive strains was significantly higher in CA-MRSA than in HA-MRSA. No significant 37 
differences were detected between the two groups in terms of antibiotic susceptibility and 38 
patients’ background information, classification of SSTIs, or symptoms of SSTIs.  39 
 40 
Key words 41 
MRSA; SCCmec; surveillance; epidemiology; SSTI  42 
Introduction 43 
Skin and soft tissue infections (SSTIs) are common in both outpatient and inpatient. 44 
Although most MRSA infections are categorized as healthcare-associated infections, 45 
those caused by community-associated MRSA (CA-MRSA), which usually carries 46 
staphylococcal cassette chromosome mec (SCCmec) types IV or V, have been reported 47 
from all over the world for over 10 years.(1,2) However, the molecular characteristics of 48 
MRSA isolated from SSTIs in Japan remain unclear, because there are only a few 49 
multicenter studies on molecular epidemiology of MRSA isolated from SSTIs in Japan. 50 
(3–5) 51 
To reveal the molecular epidemiology of MRSA isolated from patients with SSTIs in 52 
Japan, we performed genetic analysis of MRSA collected in the nationwide surveillance 53 
conducted by the Japanese Society of Chemotherapy, Japanese association for infectious 54 
diseases and Japanese society for Clinical Microbiology.(6) Additionally, we investigated 55 




Material and methods 60 
Strains and patients’ background 61 
MRSA strains were collected throughout Japanese institutions included 30 62 
dermatology departments within hospitals and 10 dermatology clinics (Supplementary 63 
Table 1) between January and October 2013, as described in a previous study.(6) Of the 64 
141 strains, 7 strains were isolated from clinics and 134 strains were isolated from 65 
hospitals. Minimum inhibitory concentration (MIC) of MRSA strains was measured in 66 
the previous study. (6) Patients’ background information was collected from all 67 
participants and anonymized for use in this study. 68 
 69 
Real-time PCR assay 70 
Bacterial DNA extraction and real-time PCR were performed as reported previously 71 
to amplify SCCmec I, SCCmec II-III, SCCmec I-II-IV, toxic shock syndrome toxin 1 72 
genes (tst), enterotoxin C genes (sec), exfoliative toxin type b genes (etb), and pvl. (7) 73 
Based on the result of real-time PCR, the strains were determined as SCCmec type I, II, 74 
III, IV, and non-typeable. (2,7–9) Based on the SCCmec type, we classified the strains 75 
into HA-MRSA (SCCmec type I, II, and III) and CA-MRSA (SCCmec type IV).(8) 76 
 77 
Ethics 78 
This study followed the principles set forth in the Declaration of Helsinki and was 79 
approved by the ethics committee of Nagasaki University Hospital (approval number, 80 
19012118).  81 
 82 
Statistical analysis 83 
In a comparative study, we used IBM SPSS version 25 (IBM Japan, Tokyo, Japan) for 84 
all statistical analyses, which were unpaired, two-tailed, and tests of significance. The 85 
statistically significant alpha level was set at ≤ 0.05. Fisher’s exact test was used to 86 
compare categorical variables. Continuous variables were expressed as mean ± standard 87 




Genetic analysis 92 
Of the 141 strains, 2 (1.4%) carried SCCmec type I, 74 (52.5%) carried SCCmec type 93 
II, 8 (5.7%) carried SCCmec III, and 57 (40.4%) carried SCCmec type IV (Fig. 1A). There 94 
was no non-typeable strain. With regard to virulence genes, 114 strains (80.9%) were 95 
positive for sec, 132 (93.6%) were positive for tst, 14 (9.9%) were positive for etb, and 9 96 
(6.4%) were positive for pvl (Fig. 1B).  97 
According to the SCCmec type, we classified the strains into HA-MRSA (n = 84) and 98 
CA-MRSA (n = 57). The percentage of sec gene-positive strains was found to be 99 
significantly higher in CA-MRSA than in HA-MRSA (89.5%, CA-MRSA and 75.0%, 100 
HA-MRSA, P = 0.048) (Fig. 1C).  101 
 102 
Comparison of patient background information between HA- and CA-MRSA 103 
According to the patients’ background information, the percentage of inpatients in the 104 
HA- and CA-MRSA groups was 36.9% and 38.6%, respectively. History of 105 
hospitalization within 1 year in the HA- and CA-MRSA groups was 45.2% and 42.1%, 106 
respectively. There were no significant differences between the two groups in patients’ 107 
background (Table 1). 108 
 109 
Differences in antibiotic susceptibility between HA-MRSA and CA-MRSA 110 
The MICs of HA-MRSA and CA-MRSA are shown in Supplementary Table 2. There 111 
was no difference in MIC50 and MIC90 between HA-MRSA and CA-MRSA. Antibiotic 112 
susceptibility of HA-MRSA and CA-MRSA is shown in Figure 2. The susceptibility rate 113 
of ciprofloxacin, levofloxacin, and moxifloxacin was lower in HA-MRSA than in CA-114 
MRSA. However, there was no significant difference in antibiotic susceptibility between 115 




We investigated the molecular epidemiology of MRSA isolated from patients with 120 
SSTIs in the Japanese nationwide surveillance. From our genetic analysis, the percentage 121 
of SCCmec type II was higher than that of SCCmec type IV. On the other hand, in the 122 
previous nationwide surveillance of CA-MRSA isolated from skin and pus samples of 123 
outpatients in Japan, the most frequent SCCmec type was IV and the second was II.(4) 124 
However, there were some differences in study design between two nationwide 125 
surveillance. MRSA strains were collected from only outpatients in the first nationwide 126 
surveillance while MRSA strains were collected from both outpatients and inpatients in 127 
this study. In addition, MRSA strains were collected from many small hospitals that 128 
possible no microbiology laboratories in the first nationwide surveillance,(4) whereas 129 
MRSA strains were collected from many university hospitals. (6) Most of the MRSA 130 
strains (95.0%) in this study were isolated from hospitals. A previous multicenter study 131 
of MRSA isolated from outpatients in Tama district of Tokyo revealed that the percentage 132 
of SCCmec type II in hospitals was higher than that in clinics.(3), which could explain 133 
why the most frequent SCCmec type was different between two nationwide surveillance.  134 
A recent multicenter study on MRSA isolated from outpatients with impetigo in 135 
Kagawa reported that the most frequent SCCmec type was V.(5) The previous study in 136 
Tama also reported the percentage of SCCmec V in hospitals and clinics were 20.0% and 137 
46.3%, respectively.(3) SCCmec V was determined as non-typeable in our method,(9) but 138 
there was no non-typeable strain in this study. There is a possibility that the difference in 139 
method between two previous studies and this study influenced the results. However, 140 
patients’ background is markedly different between two previous studies and this study. 141 
The median age of patient in Kagawa was 12, (5) and that in hospitals and clinics in Tama 142 
was 5 and 4, respectively. (3) On the other hand, the mean age was 52.5 in this study. 143 
Moreover, 72.3% of the patients in this study had underlying diseases. Since SCCmec 144 
type V was generally seen in healthy children or young athletes,(10) these differences 145 
might influence the detection of SCCmec V. In addition, there is a possibility that 146 
epidemic SCCmec type vary depending on the region, because there was no participating 147 
institution located in Tama district or Kagawa in this study. 148 
We compared virulence genes, patients’ background, and antibiotic susceptibility 149 
between HA-MRSA and CA-MRSA groups in this study. For virulence factors, the 150 
percentage of sec gene-positive strains was significantly higher in the CA-MRSA group 151 
than in HA-MRSA as previously reported.(8,11) From a comparison of patient 152 
background information, we found no significant differences between HA-MRSA and 153 
CA-MRSA groups. A percentage of inpatient in CA-MRSA group was almost as much as 154 
that in HA-MRSA. This means that hospital-acquired SSTIs was also caused by CA-155 
MRSA strain. In this study, the susceptibility rate of fluoroquinolone was lower in HA-156 
MRSA than in CA-MRSA, but there was no significant differences. A Previous studies 157 
reported that antibiotic susceptibility was different between HA-MRSA and CA-158 
MRSA.(3,4,9) 159 
There were some limitations to the current study. First, other than SCCmec typing, we 160 
did not perform a detailed molecular analysis, such as multi locus sequence typing 161 
(MLST). Recently, SCCmec type IV has been increasing in the hospital-acquired MRSA 162 
infections.(2,12) In addition, both SCCmec types II and IV were frequently found in the 163 
same clonal complex in the previous study.(5) Hence, in further nationwide surveillance, 164 
a performance of MLST is needed. Second, we analyzed MRSA strains isolated at a 165 
specific point in time. Since there is a possibility that the percentage of SCCmec type II 166 
and IV is different depending on the study period,(5) further study at other period is 167 
needed. Third, we were not able to investigate the effect of antibiotics. CA-MRSA tended 168 
to be sensitive to fluoroquinolones, but their effect remains unknown.  169 
In conclusion, this study revealed that the percentage of SCCmec type II is higher 170 
than that of SCCmec type IV in MRSA strains isolated from patients with SSTIs in 171 
Japan. Additionally, there are no significant differences in patient background or 172 
antibiotic susceptibility between HA-MRSA and CA-MRSA in this study.  173 
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Supporting information 308 
Supplementary Table 1. Participating institutions 
Institutions 
Hospitals 
Akita University Hospital, Akita 
Yamagata University Hospital, Yamagata 
University of Tsukuba Hospital, Ibaraki 
Yokohama City University Hospital, Kanagawa 
Teikyo University Hospital, Tokyo 
Tokyo Metropolitan Police Hospital, Tokyo 
Center Hospital of the National Center for Global Health and Medicine, Tokyo 
Saitama Cooperative Hospital, Saitama 
Shinshu University School of Medicine, Nagano 
  University of Yamanashi Hospital 
  Toyama University Hospital, Toyama 
  Toyama Prefectural Central Hospital, Toyama 
  Gifu Prefectural General Medical Center, Gifu 
  Ishikawa Prefectural Central Hospital, Ishikawa 
  Shiga University of Medical Science Hospital, Shiga 
  Kyoto University Hospital, Kyoto 
  Nara Medical University Hospital, Nara 
  Wakayama Medical University Hospital, Wakayama 
  Meiwa Hospital, Hyogo 
  Okayama University Hospital, Okayama 
  Hiroshima University Hospital, Hiroshima 
  Yamaguchi University Hospital, Yamaguchi 
  Tottori University Hospital, Tottori 
  Shimane University Hospital, Shimane 
  Shimane Prefectural Central Hospital, Shimane 
  Kagawa University Hospital, Kagawa 
  Ehime University Hospital, Ehime 
  Kochi Medical School Hospital, Kochi 
  Kyushu University Hospital, Fukuoka 
  Kagoshima University Hospital, Kagoshima 
 
Clinics 
Tobudaishimae Clinic, Tokyo 
Shinozaki Dermatology Clinic, Tokyo 
Kobayashi Dermatology Clinic, Tokyo 
Okuda Dermatology Clinic, Tokyo 
Go Dermatology Clinic, Tokyo 
Kikuchi Orthopedic Clinic, Tokyo 
Okada Dermatology Clinic, Tokyo 
Takeshima Dermatology Clinic, Tokyo 
Kaneko Dermatology Clinic, Saitama 
Fujimino Dermatology Clinic, Saitama 
 309 
Supplementary Table 2. Comparison of MICs between HA-MRSA and CA-MRSA 
Antibiotic 
HA-MRSA (n = 84) CA-MRSA (n = 57) 
50% 90% range  50% 90% range 
PCG 8 32 0.125 to 64 8 32 0.5 to 32 
MPIPC 64 128 4 to >128 64 > 128 4 to > 128 
ABPC  8 32 0.25 to 128 16 32 1 to 64 
SBT/ABPC 8 16 0.25 to 32 8 16 0.5 to 32 
AMPC 16 32 1 to >64 16 32 1 to 64 
CVA/AMPC 8 32 0.5 to 64 8 32 1 to 32 
PIPC 64 128 2 to >128 64 128 2 to > 128 
TAZ/PIPC-1 16 128 2 to >128 8 128 1 to > 128 
TAZ/PIPC-2 32 128 2 to 128 16 128 2 to 128 
CEZ 8 > 128 1 to > 128 8 > 128 1 to > 128 
CTM 4 > 128 1 to > 128 8 > 128 1 to > 128 
CFDN 4 > 64 0.5 to > 64 4 > 64 0.5 to > 64 
CDTR 16 > 64 1 to > 64 16 > 64 2 to > 64 
CFPN 16 > 128 2 to > 128 16 > 128 2 to > 128 
CFX 64 > 128 4 to > 128 32 > 128 4 to > 128 
CMZ 16 64 2 to 128 8 64 2 to 128 
IPM 0.5 32 ≦ 0.06 to > 64 0.5 32 ≦ 0.06 to 64 
MEPM 2 32 0.125 to 64 2 16 0.25 to 32 
FRPM 1 > 128 0.25 to > 128 1 > 128 0.25 to > 128 
CPFX 64 > 128 0.25 to > 128 16 > 128 0.125 to >128 
TFLX >16 > 16 ≦ 0.06 to > 16 >16 > 16 ≦0.06 to >16 
NDFX 2 16 ≦ 0.06 to 128 2 16 ≦0.06 to 64 
LVFX 16 > 128 0.125 to >128 8 >128 0.25 to >128 
MFLX 2 64 ≦0.06 to 128 2 64 ≦0.06 to 128 
GM 32 128 0.125 to > 128 32 64 0.125 to >128 
ABK 0.5 1 0.25 to 8 0.5 1 0.25 to 8 
EM > 128 > 128 0.5 to > 128 >128 > 128 0.25 to > 128 
CAM > 64 > 64 0.25 to > 64 >64 > 64 0.25 to > 64 
AZM > 64 > 64 0.5 to > 64 >64 > 64 0.5 to > 64 
CLDM 0.25 > 128 0.125 to > 128 0.25 >128 0.125 to > 128 
MINO 0.125 16 ≦ 0.06 to 32 0.125 16 ≦ 0.06 to 32 
VCM 1 1 0.5 to 2 1 1 0.5 to 2 
TEIC 1 2 0.5 to 2 1 2 0.25 to 2 
LZD 2 4 1 to 4 2 4 1 to 4 
FOM 32 > 128 0.5 to > 128 8 >128 0.5 to > 128 
ST 0.06 0.125 0.06 to > 8 0.06 0.125 0.06 to 0.25 
MICs, minimum inhibitory concentrations; HA-MRSA, hospital associated MRSA; CA-MRSA, 
community associated MRSA 
 310 
 311 
Figure legends 312 
Figure 1. Genetic analysis of MRSA strains.  313 
A total of 141 strains were isolated from patients with SSTI, and identified as MRSA. 314 
SCCmec type (A) and virulence genes (B) were identified using real-time PCR. We 315 
compared the virulence genes between HA-MRSA and CA-MRSA (C). 316 
sec, enterotoxin type C; tst, toxic shock syndrome toxin 1; pvl, Panton-Valentine 317 
Leucocidin; etb, exfoliative toxin type b; HA-MRSA, healthcare-associated MRSA; 318 
CA-MRSA, community-associated MRSA; NS, not significant in Fisher’s exact test. 319 
 320 
Figure 2. Comparison of antibiotic susceptibility of HA-MRSA and CA-MRSA.  321 
Resistance breakpoints were defined according to criteria from the CLSI M100-S22. 322 
CPFX, ciprofloxacin; LVFX, levofloxacin; MFLX, moxifloxacin; GM, gentamicin; EM, 323 
erythromycin, CAM, clarithromycin; AZM, azithromycin; CLDM, clindamycin; MINO, 324 
minocycline; ST, sulfamethoxazole / trimethoprim; VCM, vancomycin; TEIC, 325 
teicoplanin; LZD, linezolid. 326 
 327 
  328 
Tables 329 
Table 1. Comparison of patients’ background information between HA-MRSA and CA-MRSA 
Patients’ background 
HA-MRSA  
(n = 84) 
CA-MRSA  
(n = 57) 
P value 
n (%) n (%)  
Age      
  mean ± SD 52.5 ± 27.5 52.4 ± 29.9  
  ≦ 15 14 (16.7) 12 (21.1) NS 
  16 - 64 35 (41.7) 17 (29.8) NS 
  ≧ 65  33 (39.3) 39 (49.1) NS 
Gender, female 40 (47.6) 21 (36.8) NS 
Outpatient 53 (63.1) 35 (61.4) NS 
Complicated underlying disease 62 (73.8) 40 (70.2) NS 
History of antibiotics within 4 weeks 36 (42.9) 23 (40.4) NS 
History of hospitalization within 1 year 38 (45.2) 24 (42.1) NS 
Classification of SSTI     NS 
  Superficial SSTI 38 (45.2) 28 (49.1) NS 
  Deep-seated SSTI 35 (41.7) 19 (33.3) NS 
  Unknown 11 (13.1) 10 (17.5) NS 
Symptoms of SSTI     NS 
  Redness 65 (77.4) 39 (68.4) NS 
  Swelling 46 (54.8) 23 (40.4) NS 
  Local heat 30 (35.7) 17 (29.8) NS 
  Pain 32 (38.1) 14 (24.6) NS 
  Fever 14 (16.7) 6 (10.5) NS 





































Figure 1. Genetic analysis of MRSA strains. 
A total of 141 strains were isolated from patients with SSTI, and identified as MRSA. SCCmec type 
(A) and virulence genes (B) were identified using real-time PCR. We compared the virulence genes 
between HA-MRSA and CA-MRSA (C).
sec, enterotoxin type C; tst, toxic shock syndrome toxin 1;  pvl, Panton-Valentine Leucocidin; etb, 
exfoliative toxin type b; HA-MRSA, healthcare-associated MRSA; CA-MRSA, community-associated 
MRSA; NS, not significant in Fisher’s exact test.
(C)
Virulence genes
HA-MRSA (n = 84) CA-MRSA (n = 57) P value
n (%) n (%)
sec 63 (75.0) 51 (89.5) 0.048
tst 78 (92.9) 54 (94.7) NS
etb 10 (11.9) 4 (7.0) NS
pvl 5 (6.0) 4 (7.0) NS
Figure 2. Comparison of the antibiotic susceptibility of HA-MRSA and CA-MRSA 
Resistance breakpoints were defined according to criteria from the CLSI M100-S22. CPFX, 
ciprofloxacin; LVFX, levofloxacin; MFLX, moxifloxacin; GM, gentamicin; EM, erythromycin, CAM, 
clarithromycin; AZM, azithromycin; CLDM, clindamycin; MINO, minocycline; ST, sulfamethoxazole / 
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